Zoya M. Galushkina - Epidemiology

Author Information

Zoya M. Galushkina is affiliated with the N. F. Gamaleya National Research Center of Epidemiology and Microbiology, Ministry of Health of the Russian Federation, located in Moscow, Russia. Her research primarily focuses on the development of recombinant proteins and vaccines, with a significant emphasis on COVID-19 related studies.

Research Contributions

Zoya M. Galushkina has made substantial contributions to the field of epidemiology and microbiology, particularly in the development of recombinant proteins and epitope vaccines. Her recent work includes studies on the production of virus-neutralizing antibodies for SARS-CoV-2 and the creation of a platform for producing recombinant protein components of epitope vaccines for COVID-19 prevention. Additionally, she has explored the pharmacokinetics and bactericidal activity of lysostaphin, as well as the synthesis and characterization of human recombinant erythropoietin and bone morphogenetic proteins in Escherichia coli heterologous expression systems.

Aliases

Zoya M. Galushkina is also known by several aliases, including Z. Galushkina, Zoya M Galushkina, Z M Galushkina, Z.m. Galushkina, and Z. M. Galushkina.

Publication and Citation Metrics

Metric	Value
Total Citation Count	172
h-index	9
Total Paper Count	31

Publications:

Hybrid Proteins with Short Conformational Epitopes of the Receptor-Binding Domain of SARS-CoV-2 Spike Protein Promote Production of Virus-Neutralizing Antibodies When Used for Immunization

DOI: 10.1134/S0006297922040022

Year: 2022

Development of a Platform for Producing Recombinant Protein Components of Epitope Vaccines for the Prevention of COVID-19

DOI: 10.1134/S0006297921100096

Year: 2021

Development of approaches to the creation of an epitopic vaccine for preventing COVID-19

DOI: 10.18332/pht/142058

Year: 2021

Fusion of Lysostaphin to an Albumin Binding Domain Prolongs Its Half-Life and Bactericidal Activity in the Systemic Circulation

DOI: 10.3390/molecules24162892

Year: 2019

The Influence of Dimerization on the Pharmacokinetics and Activity of an Antibacterial Enzyme Lysostaphin

DOI: 10.3390/molecules24101879

Year: 2019

Synthesis in Escherichia coli and Characterization of Human Recombinant Erythropoietin with Additional Heparin-Binding Domain

DOI: 10.1134/S0006297918100061

Year: 2018

Recombinant human erythropoietin with additional processable protein domains: Purification of protein synthesized in Escherichia coli heterologous expression system

DOI: 10.1134/S0006297917110062

Year: 2017

Two variants of recombinant human bone morphogenetic protein-2 (rhBMP-2) with additional protein domains: Synthesis in an Escherichia coli heterologous expression system

DOI: 10.1134/S0006297917050091

Year: 2017

Optimization of rhBMP-2 active-form production in a heterologous expression system using microbiological and molecular genetic approaches

DOI: 10.3103/S0891416816040030

Year: 2016

Staphylococcus simulans recombinant lysostaphin: Production, purification, and determination of antistaphylococcal activity

DOI: 10.1134/S0006297916050072

Year: 2016

How are Gold Nanoparticles Relevant in Epidemiology?

How Effective are Current Interventions?

How Can One Be Nominated for the Lilienfeld Award?

What Factors Influence Patient Adherence?

What Contributes to Worsening Morbidity?

What Should Be Done in Case of Unauthorized Access?

What Drives Epidemiologists to Conduct Research?

What Are the Side Effects and Risks?

How is Underreporting Measured?

What Tools Are Available for Analyzing Climate Data in Epidemiology?

Partnered Content Networks

Relevant Topics